Mallinckrodt Announces Resubmission of Terlipressin to the FDA for the Treatment of Hepatorenal Syndrome

DUBLIN, June 13, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced the resubmission of the Company ' s New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news